These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18490915)

  • 1. B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL.
    Fronkova E; Muzikova K; Mejstrikova E; Kovac M; Formankova R; Sedlacek P; Hrusak O; Stary J; Trka J
    Bone Marrow Transplant; 2008 Aug; 42(3):187-96. PubMed ID: 18490915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
    Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
    Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
    Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
    Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
    Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
    Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR.
    Itälä M; Huhtinen AR; Juvonen V; Kairisto V; Pelliniemi TT; Penttilä TL; Rauhala A; Tienhaara A; Remes K
    Eur J Haematol; 2008 Aug; 81(2):100-6. PubMed ID: 18410542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
    Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
    Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of clinical utility of minimal residual disease detection in allogeneic stem cell recipients with childhood acute lymphoblastic leukemia: multi-institutional collaborative study in Japan.
    Imashuku S; Terui K; Matsuyama T; Asami K; Tsuchiya S; Ishii E; Kawa K; Kosaka Y; Eguchi H; Tsuchida M; Ikuta K; Kato S; Koizumi S; Okamura J; Morimoto A; Hibi S; Hamaoka K;
    Bone Marrow Transplant; 2003 Jun; 31(12):1127-35. PubMed ID: 12796792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of a new strategy for minimal residual disease monitoring in children with B-precursor acute lymphoblastic leukemia].
    Bonjean B; Grollet L; Visentin E; Sigaux F; Cayuela JM
    Ann Biol Clin (Paris); 2004; 62(4):465-70. PubMed ID: 15297244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia.
    Robillard N; Cavé H; Méchinaud F; Guidal C; Garnache-Ottou F; Rohrlich PS; Avet-Loiseau H; Garand R
    Haematologica; 2005 Nov; 90(11):1516-23. PubMed ID: 16266899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of clonal stability of minimal residual disease targets between 1st and 2nd relapse of childhood precursor B-cell acute lymphoblastic leukemia.
    Guggemos A; Eckert C; Szczepanski T; Hanel C; Taube T; van der Velden VH; Graf-Einsiedel H; Henze G; Seeger K
    Haematologica; 2003 Jul; 88(7):737-46. PubMed ID: 12857551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
    Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
    Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pattern of immunoglobulin and T-cell receptor (Ig/TCR) gene rearrangements in Polish pediatric acute lymphoblastic leukemia patients--implications for RQ-PCR-based assessment of minimal residual disease.
    Dawidowska M; Derwich K; Szczepański T; Jółkowska J; van der Velden VH; Wachowiak J; Witt M
    Leuk Res; 2006 Sep; 30(9):1119-25. PubMed ID: 16476479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia.
    Schwarz AK; Stanulla M; Cario G; Flohr T; Sutton R; Möricke A; Anker P; Stroun M; Welte K; Bartram CR; Schrappe M; Schrauder A
    Ann Hematol; 2009 Sep; 88(9):897-905. PubMed ID: 19165483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.
    Kerst G; Kreyenberg H; Roth C; Well C; Dietz K; Coustan-Smith E; Campana D; Koscielniak E; Niemeyer C; Schlegel PG; Müller I; Niethammer D; Bader P
    Br J Haematol; 2005 Mar; 128(6):774-82. PubMed ID: 15755280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
    Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
    J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heteroduplex PCR analysis of rearranged immunoglobulin genes for clonality assessment in multiple myeloma.
    García-Sanz R; López-Pérez R; Langerak AW; González D; Chillón MC; Balanzategui A; Mateos MV; Alaejos I; González M; Van Dongen JJ; San Miguel JF
    Haematologica; 1999 Apr; 84(4):328-35. PubMed ID: 10190947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry.
    Mejstríková E; Fronková E; Kalina T; Omelka M; Batinić D; Dubravcić K; Pospísilová K; Vásková M; Luria D; Cheng SH; Ng M; Leung Y; Kappelmayer J; Kiss F; Izraeli S; Stark B; Schrappe M; Trka J; Starý J; Hrusák O
    Pediatr Blood Cancer; 2010 Jan; 54(1):62-70. PubMed ID: 19760767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
    Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
    Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
    van der Velden VH; Cazzaniga G; Schrauder A; Hancock J; Bader P; Panzer-Grumayer ER; Flohr T; Sutton R; Cave H; Madsen HO; Cayuela JM; Trka J; Eckert C; Foroni L; Zur Stadt U; Beldjord K; Raff T; van der Schoot CE; van Dongen JJ;
    Leukemia; 2007 Apr; 21(4):604-11. PubMed ID: 17287850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.
    Sarasquete ME; García-Sanz R; González D; Martínez J; Mateo G; Martínez P; Ribera JM; Hernández JM; Lahuerta JJ; Orfão A; González M; San Miguel JF
    Haematologica; 2005 Oct; 90(10):1365-72. PubMed ID: 16219573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.